This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Menarini Industrie Farmaceutiche Riunite.
Costs included those for treatment, administration, disease management, disease complications and treatment-emergent adverse events.
Reference
Vlachaki I, et al. Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK. European Journal of Health Economics : 21 Sep 2021. Available from: URL: https://doi.org/10.1007/s10198-021-01375-0
Rights and permissions
About this article
Cite this article
Vaborem may be cost effective for carbapenem-resistant Enterobacteriaceae infections in the UK. PharmacoEcon Outcomes News 888, 33 (2021). https://doi.org/10.1007/s40274-021-08083-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08083-9